We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

e-Therapeutics Outlines Goals for 2012

e-Therapeutics Outlines Goals for 2012

e-Therapeutics Outlines Goals for 2012

e-Therapeutics Outlines Goals for 2012

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "e-Therapeutics Outlines Goals for 2012"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Drug discovery and development company e-Therapeutics plc provides an update on its goals and expectations for 2012.

• Four drugs to enter clinical trials
- ETS2101 (anti-cancer drug; phase I programme starting in Q1)
- ETX1153c (phase I trial for C. difficile infection starting in Q2)
- ETS6103 (anti-depressant; phase IIb trial starting in Q3)
- ETX1153a (phase I trial in MRSA starting in Q4)

• First data expected from clinical trials programme
- ETS2101 - initial findings from phase I programme in Q4
- ETX1153c - phase I data in Q4

e-Therapeutics’ CEO, Professor Malcolm Young, said: “This is an important year for e-Therapeutics, as we advance multiple drugs into the clinic and look forward to the first data from our programme of trials. We remain equally focused on drug discovery, where our strengthened team is on track to deliver new candidates for development next year.”

An overview of the Company’s strategy, drug discovery platform and clinical development programmes will be presented by Professor Young at the Biotech Showcase Conference at the Parc 55 Wyndham Hotel in San Francisco on Wednesday 11 January at 10.30 am PST.